公开(公告)号：US11554109B2

公开(公告)日：2023-01-17

申请号：US17708706

申请日：2022-03-30

Applicant: Kowa Company, Ltd.

Inventor： Ryu Oshima ,  Masatoshi Ito ,  Chisato Nagai

IPC: A61K31/423 ,  A61K31/34 ,  A61K31/4152 ,  A61K31/427 ,  A61K31/4353 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7034 ,  A61K38/13 ,  A61P3/06 ,  A61K31/7048 ,  A61K45/06

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy).
A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

公开(公告)号：US20220054459A1

公开(公告)日：2022-02-24

申请号：US17515945

申请日：2021-11-01

Applicant: Kowa Company, Ltd.

Inventor： Yusuke Sasaki ,  Masato Asahiyama ,  Toshiya Tanaka

IPC: A61K31/423 ,  A61P1/16

Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

公开(公告)号：US20220023286A1

公开(公告)日：2022-01-27

申请号：US17498822

申请日：2021-10-12

Applicant: National University Corporation Hamamatsu University School of Medicine ,  Kowa Company, Ltd.

Inventor： Naoki Unno ,  Hiroki Tanaka ,  Tatsuro Yata ,  Keisuke Inoue ,  Yuichi Makinose ,  Noboru Kaneta

IPC: A61K31/4704 ,  A61P9/14

Abstract: The present invention addresses the problem of providing a therapeutic agent for abdominal aortic aneurysms, with which pharmacotherapy is possible.
The present invention provides a therapeutic agent for an aortic aneurysm comprising, as an active component, (−)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate of these.

公开(公告)号：US20220000786A1

公开(公告)日：2022-01-06

申请号：US17418091

申请日：2019-12-27

Applicant: KOWA COMPANY, LTD.

Inventor： Chisa NISHIDA

IPC: A61K9/20 ,  A61K9/16 ,  A61K31/423

Abstract: Provided is a technique for suppressing the composition changes between pemafibrate, a salt thereof or a solvate thereof and (meth)acrylic acid-based polymers. A pharmaceutical preparation is provided by storing a pharmaceutical composition containing the following components (A) and (B) in a tight package: (A) pemafibrate, a salt thereof or a solvate thereof; and (B) a (meth)acrylic acid-based polymer.

公开(公告)号：US11166948B2

公开(公告)日：2021-11-09

申请号：US16647448

申请日：2018-09-13

Applicant: National University Corporation Hamamatsu University School of Medicine ,  Kowa Company, Ltd.

Inventor： Naoki Unno ,  Hiroki Tanaka ,  Tatsuro Yata ,  Keisuke Inoue ,  Yuichi Makinose ,  Noboru Kaneta

IPC: A61K31/4704 ,  A61P9/14 ,  C07D215/227

Abstract: The present invention addresses the problem of providing a therapeutic agent for abdominal aortic aneurysms, with which pharmacotherapy is possible.
The present invention provides a therapeutic agent for an aortic aneurysm comprising, as an active component, (−)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate of these.

公开(公告)号：US20210307604A1

公开(公告)日：2021-10-07

申请号：US17266973

申请日：2019-08-07

Applicant: Kowa Company, Ltd.

Inventor： Kazunori MATSUMURA ,  Akio KAWAKAMI

IPC: A61B3/11 ,  A61B3/00 ,  A61B3/15

Abstract: The present application discloses an ophthalmic photographing device that enables easy detection of a pupil diameter. The present invention pertains to an ophthalmic photographing device that is provided with: an anterior ocular segment illumination means for illuminating an anterior ocular segment of an eye of a subject with invisible light; an imaging element that is sensitive to at least invisible light and that is for capturing an image of the eye of the subject; and a processing means for processing an image captured by the imaging element, wherein when an image of an index projected onto the anterior ocular segment fulfills a prescribed condition, the processing means starts detection of a pupil diameter of the eye of the subject using an image formed on the imaging element by means of light reflected from the anterior ocular segment that has been illuminated with the invisible light from the anterior ocular segment illumination means.

公开(公告)号：US20210290598A1

公开(公告)日：2021-09-23

申请号：US17053223

申请日：2019-05-07

Applicant: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY ,  KOWA COMPANY, LTD.

Inventor： Hiroshi ITO ,  Kazufumi NAKAMURA ,  Masatoki YOSHIDA ,  Keisuke INOUE

IPC: A61K31/423 ,  A61K31/40 ,  A61K31/405 ,  A61K31/366 ,  A61K31/47 ,  A61K31/22 ,  A61K31/505 ,  A61P9/00

Abstract: Provided is a medicament useful for cardiovascular diseases.
An agent for prevention and/or treatment of a cardiovascular diseases, comprising a combination of pemafibrate or a salt thereof and an HMG-CoA reductase inhibitor.

公开(公告)号：US20210267753A1

公开(公告)日：2021-09-02

申请号：US17274401

申请日：2019-09-09

Applicant: Kowa Company, Ltd.

Inventor： Norio OBA

IPC: A61F2/16

Abstract: An intraocular lens insertion apparatus which allows the intraocular lens to behave more stably. The intraocular lens insertion apparatus includes a substantially tubular apparatus body which has, at a tip end thereof, an insertion tube part for inserting an intraocular lens in a folded state into an eye, the intraocular lens having a lens body and a support, a storage which stores the intraocular lens, and an extruding member which moves the intraocular lens in the insertion tube part by pushing the intraocular lens, and the extruding member has a tip end part having a first protrusion protruding to one side in a left-right direction and a second protrusion protruding to the other side in the left-right direction.

公开(公告)号：US11013722B2

公开(公告)日：2021-05-25

申请号：US16272050

申请日：2019-02-11

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397 ,  A61K45/06

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

公开(公告)号：US10993799B2

公开(公告)日：2021-05-04

申请号：US15768741

申请日：2016-09-28

Applicant: KOWA COMPANY, LTD.

Inventor： Kenichi Kobayashi ,  Shuji Abe ,  Genyo Midorikawa

IPC: A61F2/16 ,  A61F9/007 ,  A61B17/00

Abstract: It is provided an intraocular lens insertion system that achieves a preferable insertion of an intraocular lens without using viscoelastic material in an eyeball. The intraocular lens insertion system includes an intraocular lens insertion apparatus configured to use a predetermined driving force to move an intraocular lens and insert the intraocular lens into an eyeball, an irrigating solution infusion apparatus configured to infuse irrigating solution into the eyeball, a driving source configured to deliver the predetermined driving force to the intraocular lens insertion apparatus, an irrigating solution source configured to deliver the irrigating solution to the irrigating solution infusion apparatus, and a switching unit configured to switch in a multistage manner a control of a delivery of the irrigating solution from the irrigating solution source to the irrigating solution infusion apparatus and a control of a delivery of the predetermined driving force from the driving source to the intraocular lens insertion apparatus.